Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021

BACKGROUND: One year into the COVID‐19 pandemic, the cumulative number of confirmed COVID‐19 cases in Norway was still low. In January 2021, when the Norwegian COVID‐19 vaccination campaign started, the national seroprevalence estimate of SARS‐CoV‐2 antibodies was 3.2%. We have conducted a nationwid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunheim, Gro, Rø, Gunnar Øyvind Isaksson, Chopra, Adity, Aase, Audun, Kran, Anne‐Marte Bakken, Vaage, John Torgils, Lund‐Johansen, Fridtjof, Hungnes, Olav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349429/
https://www.ncbi.nlm.nih.gov/pubmed/35770841
http://dx.doi.org/10.1111/irv.13024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349429/
https://www.ncbi.nlm.nih.gov/pubmed/35770841
http://dx.doi.org/10.1111/irv.13024

Ejemplares similares